Overview

This briefing summarises the latest business, regulatory and legal developments in China for drug, device, life science and health care companies. Included in this edition are details on the following:

• Beijing hospital requirements: overuse of antibiotics


• Interim measures on appraisal of traditional Chinese medicine hospitals


• Two pharmaceutical companies fined for monopolising compound reserpine API


• China to build ADR monitoring system


• China finalises healthcare reform 12th five year plan


• China to launch large-scale survey on traditional Chinese medicine resources


• All the latest regulation developments in life science and health care

For the full details on all these stories and more, click 'View Briefing'.